The firm is prioritizing development of its anti-DKK1 antibody sirexatamab following promising Phase II results in microsatellite-stable colorectal cancer.

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the ...

With fiscal 2025 being a low base year due to losses, earnings per share are forecast to more than double by financial year ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

Cardiff Oncology is entering a pivotal stage with a strong cash runway and compelling early data in first-line RAS-mutant ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025.

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...